Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma:an efficacy and cost-effectiveness study

ABSTRACT

Objective: To evaluate efficacy and costeffectiveness of budesonide/formoterol (Symbicort) maintenance (one dose once or twice daily) plus additional doses as needed (Symbicort Maintenance And Reliever Therapy, SMART) compared with a higher fixed dose of budesonide/ formoterol with formoterol as needed in patients with persistent asthma.

* Symbicort is a registered trade name of the AstraZeneca group of companies

Study design and methods: 6‐month, open, randomised study of 465 patients either not well controlled on an inhaled corticosteroid (ICS), or well controlled on a combination of ICS and a long-acting β₂‐agonist (LABA). Treatments: budesonide/formoterol 160/4.5 µg, one inhalation, once or twice daily maintenance plus additional doses as-needed (1 × SMART or 2 × SMART), or budesonide/formoterol 160/4.5 µg two inhalations twice daily plus formoterol 4.5 µg as needed (2 × 2 FIX + F). Children 6–11 years old used an 80/4.5 µg dose strength. Primary variables of efficacy were the changes in the Asthma Control Questionnaire (ACQ₅) and morning peak expiratory flow (PEF).

Results: Mean age of patients 40 years (range 6–82 years); 53% female. No differences between the groups were found in ACQ₅ scores or asthma exacerbation rates. Morning PEF was higher in the 2 × 2 FIX + F group vs. the 1 × SMART and 2 × SMART groups (differences 13 L/min and 9 L/min, respectively; p < 0.002). The 1 × SMART group showed a significant decrease in asthma controlled days compared with the two other groups. No difference was seen between the 2 × SMART group and the 2 × 2 FIX + F group. Treatment costs were significantly lower in the SMART groups compared with the 2 × 2 FIX + F group.

Conclusion: Compared with the 2 × 2 FIX + F treatment the use of budesonide/formoterol was 30–40% lower in the SMART groups while maintaining equal ACQ₅ scores. Daily asthma control improved equally with 2 × SMART compared to 2 × 2 FIX + F with a reduction in asthma medication cost. The one dose once daily maintenance treatment (1 × SMART) resulted in a low level of treatment failure (exacerbations) but led to more days with symptoms. Therefore, a daily dose of two inhalations seems to be the lowest appropriate dose in patients with moderate persistent asthma.

Key words: :

• Asthma
• Budesonide/formoterol
• Maintenance therapy
• Reliever therapy
• Symbicort Maintenance And Reliever Therapy (SMART)

Notes

* Symbicort is a registered trade name of the AstraZeneca group of companies